Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Immatics $125 million follow-on offering
We advised Immatics on the offering
Merck $8 billion notes offering
We advised the underwriters on the notes offering
Aradigm $20 million Series A financing round
We advised Frist Cressey Ventures, which led the round
Illumina $500 million notes offering
We advised the underwriters on the offering
Daffodil Health $16.6 million Series A financing round
We advised Flare Capital, which led the round
Olema Pharmaceuticals $218.5 million follow-on offering
We advised the underwriters on the offering
Bristol Myers Squibb $7 billion cash tender offer
We advised the dealer managers on the tender offer
Inventiva $172.5 million follow-on offering
We advised the underwriters on the offering
Ionis Pharmaceuticals $770 million convertible senior notes offering
We advised the representatives of the initial purchasers on the offering
GRAIL $300 million at-the-market offering
We advised the sales agents on the offering